Latest & greatest articles for celecoxib

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on celecoxib or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on celecoxib and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for celecoxib

1. BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)

BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004) 30279015 2018 10 03 1873-7560 2018 Sep 29 European urology Eur. Urol. BOXIT-A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). S0302-2838(18)30683-3 10.1016/j.eururo.2018.09.020 Non-muscle-invasive bladder (...) cancer (NMIBC) has a significant risk of recurrence despite adjuvant intravesical therapy. To determine whether celecoxib, a cyclo-oxygenase 2 inhibitor, reduces the risk of recurrence in NMIBC patients receiving standard treatment. BOXIT (CRUK/07/004, ISRCTN84681538) is a double-blinded, phase III, randomised controlled trial. Patients aged ≥18 yr with intermediate- or high-risk NMIBC were accrued across 51 UK centres between 1 November 2007 and 23 July 2012. Patients were randomised (1:1

EvidenceUpdates2018

2. Celecoxib

Celecoxib Top results for celecoxib - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for celecoxib The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

3. Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness

Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness | CADTH.ca Find the information you need Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Gabapentin, Celecoxib, and Acetaminophen for the Prevention of Post-Operative Pain: Clinical Effectiveness Published on: July 31, 2017 (...) Project Number: RB1124-000 Product Line: Research Type: Drug Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of pre-operative administration of gabapentin to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of celecoxib to reduce post-operative pain following orthopedic surgery? What is the clinical effectiveness of pre-operative administration of acetaminophen to reduce post

Canadian Agency for Drugs and Technologies in Health - Rapid Review2017

4. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT)

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT) 28533290 2017 05 23 2017 05 23 1468-2060 2017 May 22 Annals of the rheumatic diseases Ann. Rheum. Dis. Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT (...) ). annrheumdis-2016-210860 10.1136/annrheumdis-2016-210860 Chondroitin sulfate 800 mg/day (CS) pharmaceutical-grade in the management of symptomatic knee osteoarthritis consistent with the European Medicines Agency guideline. A prospective, randomised, 6-month, 3-arm, double-blind, double-dummy, placebo and celecoxib (200 mg/day)-controlled trial assessing changes in pain on a Visual Analogue Scale (VAS) and in the Lequesne Index (LI) as coprimary endpoints. Minimal-Clinically Important Improvement (MCII

EvidenceUpdates2017

5. Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial.

Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial. BACKGROUND: Present guidelines are conflicting for patients at high risk of both cardiovascular and gastrointestinal events who continue to require non-steroidal anti-inflammatory drugs (NSAIDs). We hypothesised that a cyclooxygenase-2-selective NSAID plus proton (...) staff member randomly assigned (1:1) patients who were negative for Helicobacter pylori with a computer-generated list of random numbers to receive oral administrations of either celecoxib 100 mg twice per day plus esomeprazole 20 mg once per day or naproxen 500 mg twice per day plus esomeprazole 20 mg once per day for 18 months. All patients resumed aspirin 80 mg once per day. Both patients and investigators were masked to their treatments. The primary endpoint was recurrent upper gastrointestinal

Lancet2017

6. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.

Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. BACKGROUND: The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal antiinflammatory drugs (NSAIDs), remains uncertain. METHODS: Patients who required NSAIDs for osteoarthritis or rheumatoid arthritis and were at increased cardiovascular risk were randomly assigned to receive celecoxib, ibuprofen, or naproxen. The goal of the trial was to assess the noninferiority of celecoxib with regard (...) to the primary composite outcome of cardiovascular death (including hemorrhagic death), nonfatal myocardial infarction, or nonfatal stroke. Noninferiority required a hazard ratio of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-treat population and of 1.40 or lower in the on-treatment population. Gastrointestinal and renal outcomes were also adjudicated. RESULTS: A total of 24,081 patients were randomly assigned to the celecoxib group (mean [±SD] daily dose

NEJM2016

7. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT)

Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT) 27705888 2016 10 05 2017 04 03 1522-9645 2016 Oct 04 European heart journal Eur. Heart J. Randomized trial of switching from prescribed non-selective non-steroidal anti-inflammatory drugs to prescribed celecoxib: the Standard care vs. Celecoxib Outcome Trial (SCOT). ehw387 Selective cyclooxygenase-2 inhibitors (...) and conventional non-selective non-steroidal anti-inflammatory drugs (nsNSAIDs) have been associated with adverse cardiovascular (CV) effects. We compared the CV safety of switching to celecoxib vs. continuing nsNSAID therapy in a European setting. Patients aged 60 years and over with osteoarthritis or rheumatoid arthritis, free from established CV disease and taking chronic prescribed nsNSAIDs, were randomized to switch to celecoxib or to continue their previous nsNSAID. The primary endpoint

EvidenceUpdates2016

8. Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions

Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions UTCAT3052, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Preoperative Administration of Celecoxib (Celebrex) is Effective for Managing Postoperative Pain In Third Molar Extractions Clinical Question In a healthy adult, is preoperative administration of the nonsteroidal anti-inflammatory drug (...) (NSAID) celecoxib (Celebrex), as compared to a placebo, an effective method for reducing postoperative pain following a third molar extraction? Clinical Bottom Line For patients requiring third molar extractions, celecoxib (Celebrex) is an effective treatment medication when compared to placebo for managing and reducing of postoperative pain. However, more uniform research methodology is required for the further evaluation of celecoxib and other NSAIDs. This result is supported by a randomized

UTHSCSA Dental School CAT Library2016

9. Effects of Combined Application of Muscle Relaxants and Celecoxib Administration After Total Knee Arthroplasty (TKA) on Early Recovery: A Randomized, Double-Blind, Controlled Study

Effects of Combined Application of Muscle Relaxants and Celecoxib Administration After Total Knee Arthroplasty (TKA) on Early Recovery: A Randomized, Double-Blind, Controlled Study 23561916 2013 09 03 2014 05 12 2015 11 19 1532-8406 28 8 2013 Sep The Journal of arthroplasty J Arthroplasty Effects of combined application of muscle relaxants and celecoxib administration after total knee arthroplasty (TKA) on early recovery: a randomized, double-blind, controlled study. 1301-5 10.1016/j.arth (...) .2012.10.002 S0883-5403(13)00060-0 The purpose of this study was to evaluate the effectiveness of application of muscle relaxants and celecoxib in early recovery after total knee arthroplasty (TKA). One hundred and fifty patients were randomized 1:1:1 to receive either both of muscle relaxants and celecoxib or muscle relaxants alone or placebo for 2 weeks (50 patients in each group). VAS pain scores as primary efficacy, active range of motion, morphine consumption, blood loss, and postoperative

EvidenceUpdates2013

10. The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial

The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial The cost-effectiveness of celecoxib vs diclofenac in the treatment of osteoarthritis in the UK: an update to the NICE model using data from the CONDOR trial Brereton N, Winn B, Akehurst (...) R Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study evaluated the cost-effectiveness of celecoxib plus a proton pump inhibitor (PPI), compared with diclofenac plus a PPI, for patients with osteoarthritis. The authors

NHS Economic Evaluation Database.2013

11. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial

Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial 22452894 2012 05 04 2012 06 26 2016 12 15 1474-5488 13 5 2012 May The Lancet. Oncology Lancet Oncol. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial. 549-58 10.1016/S1470-2045(12)70088 (...) -8 Long-term hormone therapy alone is standard care for metastatic or high-risk, non-metastatic prostate cancer. STAMPEDE--an international, open-label, randomised controlled trial--uses a novel multiarm, multistage design to assess whether the early additional use of one or two drugs (docetaxel, zoledronic acid, celecoxib, zoledronic acid and docetaxel, or zoledronic acid and celecoxib) improves survival in men starting first-line, long-term hormone therapy. Here, we report the preplanned

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

12. Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina.

Effects of Celecoxib On Restenosis after Coronary Intervention and Evolution of Atherosclerosis (Mini-COREA) Trial: celecoxib, a double-edged sword for patients with angina. 22408034 2012 11 02 2013 04 18 2015 11 19 1522-9645 33 21 2012 Nov European heart journal Eur. Heart J. Effects of celecoxib on restenosis after coronary intervention and evolution of atherosclerosis (Mini-COREA) trial: celecoxib, a double-edged sword for patients with angina. 2653-61 10.1093/eurheartj/ehs001 (...) In the previous COREA-TAXUS trial, a 6-month adjunctive use of celecoxib reduced target-lesion revascularization (TLR) without increased thrombotic risk. We aimed to confirm the effects of 3-month celecoxib in patients receiving drug-eluting stent (DES) implantation in the larger prospective, randomized trial. Patients (n = 909) treated for native coronary lesions were randomized into four groups: the control or the celecoxib group with stratification by stents: paclitaxel-eluting stent (PES) or zotarolimus

EvidenceUpdates2012

13. Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway

Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway Cost-effectiveness evaluation of etoricoxib versus celecoxib and nonselective NSAIDs in the treatment of ankylosing spondylitis in Norway Jansen JP, Taylor SD Record Status This is a critical abstract of an economic (...) , the study was good with adequate reporting of the methods, sources of data, and results. Given the scope of the study, the authors’ conclusions appear to be appropriate. Type of economic evaluation Cost-utility analysis Study objective The objective was to estimate the cost-effectiveness of etoricoxib, relative to celecoxib and non-selective non-steroidal anti-inflammatory drugs (NSAIDs), in the initial treatment of ankylosing spondylitis, in Norway. Interventions The interventions were etoricoxib 90mg

NHS Economic Evaluation Database.2012

14. Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer

Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Cost-effectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer Squires H, Tappenden P, Cooper K, Carroll C, Logan R, Hind D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of aspirin, celecoxib, or calcium for the prevention of colorectal cancer, with a screening programme, for the general population or those who had undergone colorectal polypectomy. Calcium chemoprevention was likely to be cost-effective after polypectomy, but the evidence was weak. Aspirin could be cost

NHS Economic Evaluation Database.2012

17. Efficacy of low-dose celecoxib in patients with acute pain

Efficacy of low-dose celecoxib in patients with acute pain 21459680 2011 07 06 2011 11 03 2015 11 19 1528-8447 12 7 2011 Jul The journal of pain : official journal of the American Pain Society J Pain Efficacy of low-dose celecoxib in patients with acute pain. 756-63 10.1016/j.jpain.2010.12.014 The sore throat pain model was used to evaluate single-dose effects of celecoxib 50 and 100 mg over 6 hours in the treatment of acute pharyngeal pain. Multiple-dose effects of 50-mg bid and 100 mg (...) followed by 50 mg over 6 to 24 hours were also evaluated. Under double-blind, randomized, placebo-controlled conditions, 269 adults with confirmed acute pharyngitis rated throat pain intensity, throat soreness, difficulty swallowing, and sore throat pain relief over 24 hours. For the primary efficacy analysis (SPID2), patients receiving celecoxib 100 mg during the first 2 hours after the first dose had significantly higher mean scores than patients in the placebo group (P < .0003). Efficacy was also

EvidenceUpdates2011

18. The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery

The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery 21156974 2011 01 24 2011 02 28 2015 11 19 1526-7598 112 2 2011 Feb Anesthesia and analgesia Anesth. Analg. The effects of oral ibuprofen and celecoxib in preventing pain, improving recovery outcomes and patient satisfaction after ambulatory surgery. 323-9 10.1213/ANE.0b013e3182025a8a Nonsteroidal antiinflammatory drugs have become increasingly popular (...) as part of multimodal analgesic regimens for pain management in the ambulatory setting. We designed this randomized, double-blind, placebo-controlled study to evaluate the effect of postoperative administration of either a nonselective nonsteroidal antiinflammatory drug (ibuprofen) or the cyclooxygenase-2 selective inhibitor (celecoxib when administered as part of a multimodal analgesic regimen) on the severity of pain, the need for rescue analgesics, and clinically relevant patient outcomes after

EvidenceUpdates2011

19. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness

Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness CADTH Record Status This is a bibliographic (...) record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-selective non-steroidal anti-Inflammatory drugs and proton pump inhibitors: clinical effectiveness, safety, and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Limited evidence showed that celecoxib versus non-COX-2 selective non-steroidal

Health Technology Assessment (HTA) Database.2011

20. Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness

Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness CADTH Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Celecoxib versus non-COX-2 selective non-steroidal anti-inflammatory drugs: a review of the clinical effectiveness, safety, and cost effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2011 Authors' conclusions Evidence from five systematic reviews and one health technology assessment found that celecoxib had

Health Technology Assessment (HTA) Database.2011